Sodium oxybate for the treatment of narcolepsy

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.2, 2005-02, pp. : 329-335

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Narcolepsy, a lifelong disease with diverse symptoms, poses a therapeutic challenge to physicians. Psychomotor stimulants are used to provide some relief from excessive sleepiness, whereas a variety of other medications have traditionally been used to treat the other symptoms of this disorder. Cataplexy, consisting of sudden episodes of bilateral skeletal muscle weakness, has long been treated with tricyclic antidepressants or selective serotonin re-uptake inhibitors. Although these drugs have brought relief to some patients, they cause intolerable adverse effects in others, whereas still others become tolerant to their beneficial effects. In July of 2002, sodium oxybate was approved by the US FDA for the treatment of cataplexy, representing a significant advance in the treatment of this unusual disease. The following drug evaluation summarises the role of this novel medication in the practice of sleep medicine.